Large Outflow of Money Witnessed in Sage Therapeutics

Sage Therapeutics (SAGE) : The value of composite uptick trades was $0.68 million, whereas, the value of composite downtick trades was $1.54 million. The uptick to downtick ratio stood at 0.44 with a negative money flow of ($0.86) Million during Fridays trading session. The block trades money flow was negative ($0.49 million). The transaction of the trades on downticks amounted to $0.49 million, which confirms investors selling on the strength of price. Sage Therapeutics (SAGE) gained 73 cents at $44.12, an increase of 1.68% over the previous days close.


Sage Therapeutics (SAGE) : The highest short term price target forecast on Sage Therapeutics (SAGE) is $121 and the lowest target price is $18. A total of 7 equity analysts are currently covering the company. The average price of all the analysts is $75.14 with a standard deviation of $33.18.

Sage Therapeutics (NASDAQ:SAGE): stock turned positive on Friday. Though the stock opened at $43.54, the bulls momentum made the stock top out at $44.97 level for the day. The stock recorded a low of $43.25 and closed the trading day at $44.38, in the green by 2.28%. The total traded volume for the day was 448,646. The stock had closed at $43.39 in the previous days trading.

In a related news, The Securities and Exchange Commission has divulged that Robichaud Albert, (Chief Scientific Officer) of Sage Therapeutics, Inc., had unloaded 22,000 shares at an average price of $40 in a transaction dated on July 12, 2016. The total value of the transaction was worth $880,000.

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Companys lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.